LTR Pharma Limited (AU:LTP) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
LTR Pharma Limited has made significant strides with its innovative erectile dysfunction nasal spray, SPONTAN, now prescribed globally under early access schemes. A strategic partnership with Aptar Pharma aims to boost SPONTAN’s commercialization, while a completed clinical study indicates the spray’s rapid absorption, potentially disrupting the global market. With a solid cash balance of $12.05 million, LTR Pharma is well-positioned for future growth and market expansion.
For further insights into AU:LTP stock, check out TipRanks’ Stock Analysis page.